



The lncRNA-miRNA-mRNA ceRNA network in mural granulosa cells of patients with polycystic ovary syndrome: an analysis of Gene Expression Omnibus data

Hengxi Chen^{1,2}, Shuting Cheng³, Wei Xiong^{1,2}, Xin Tan^{1,2}

¹Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China; ²Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China; ³NHC Key Laboratory of Chronobiology (Sichuan University), West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, China

Contributions: (I) Conception and design: H Chen, X Tan; (II) Administrative support: X Tan; (III) Provision of study materials or patients: H Chen; (IV) Collection and assembly of data: H Chen; (V) Data analysis and interpretation: H Chen, S Cheng, W Xiong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Xin Tan. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. Email: tan8336@icloud.com.

Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrine abnormalities in women of reproductive age. In this study, we set out to construct a molecular long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) network according to the competitive endogenous RNA (ceRNA) theory and obtain insights into the related biological characteristics and pathways.

Methods: We downloaded two gene expression profile datasets of mural granulosa cells (MGCs) of women with PCOS and healthy women without PCOS (GSE84376 and GSE106724) from Gene Expression Omnibus (GEO) DataSets. Using GEO2R, we identified the mRNAs and non-coding RNAs with differential expression. The DIANA-microT-CDS algorithm was applied to predict the genes targeted by the differentially expressed miRNAs. The lncRNA-miRNA interactions were predicted using DIANA-LncBase v2. Then, we constructed the lncRNA-miRNA-mRNA network. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was employed to identify the functions and enriched pathways of the genes. Subsequently, STRING was used to construct the protein-protein interaction (PPI) network. cytoHubba in Cytoscape was used to rank the hub genes, and finally, PPI modules were screened with Cytoscape MCODE.

Results: There were 462 mRNAs, 2,464 lncRNAs, and 55 miRNAs which showed differential expression between the MGCs of patients with PCOS and those of healthy controls. Based on the PPI analysis, differentially expressed genes (DEGs) were significantly enriched in retinol metabolism, drug metabolism—cytochrome P450, malaria, the Hippo signaling pathway, and glycine, serine, and threonine metabolism. The ceRNA network contained 71 lncRNA nodes, 14 miRNA nodes, and 69 mRNA nodes, as well as 167 edges. We identified some novel genes and non-coding RNAs that might be involved in PCOS, including *CD163*, *MRC1*, *VSIG4*, *CCL2*, *CCR2*, *SPP1*, *hsa-miR-3135b*, *hsa-miR-4649-3p*, *hsa-miR-1231*, *hsa-miR-3609*, and *hsa-miR-4433b-3p*.

Conclusions: This study identified a novel lncRNA-miRNA-mRNA network based on the ceRNA mechanism in PCOS. Some novel genes and non-coding RNAs that may be involved in the occurrence and development of PCOS were excavated, including *CD163*, *MRC1*, *VSIG4*, *CCL2*, *CCR2*, *SPP1*, *hsa-miR-3135b*, *hsa-miR-4649-3p*, *hsa-miR-1231*, *hsa-miR-3609*, and *hsa-miR-4433b-3p*. However, our findings need to be validated by *in vivo* and *in vitro* experiments.

Keywords: Polycystic ovary syndrome (PCOS); competitive endogenous RNA network (ceRNA network); bioinformatics analysis

Submitted May 12, 2021. Accepted for publication Jun 22, 2021.

doi: 10.21037/atm-21-2696

View this article at: <https://dx.doi.org/10.21037/atm-21-2696>

Introduction

Polycystic ovary syndrome (PCOS) is a highly prevalent hormone disorder in women of childbearing age as well as a prominent risk factor for female infertility. It is characterized by hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology, and metabolic disorders (including obesity, insulin resistance, and diabetes) (1,2). Despite the lack of clarity about PCOS at the etiological level, the majority of scientists agree that genetic factors play a pivotal role in the development and maintenance of the disorder.

Protein-coding genes comprise <2% of the human genome, while non-coding RNAs make up >90% of genomic transcription products (3). Non-coding RNAs include microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), with lengths measuring 18–25 nucleotides and >200 nucleotides, respectively. At one point, scientists believed that lncRNAs were transcriptional “noise”, but increasing evidence has revealed that they are involved in various human diseases, such as cancers and reproductive system diseases (4,5). lncRNAs carry out an important molecular role by interacting with miRNAs, messenger RNAs (mRNAs), and even proteins. Among these mechanisms, lncRNAs function as competitive endogenous RNAs (ceRNAs) by communicating with mRNAs via competition for shared miRNAs (6,7).

In recent years, many lncRNAs and miRNAs were found to be associated with PCOS, such as lncRNA HOTAIR, miR-23a, and miR-23b (8,9). Fu et al constructed a lncRNA-miRNA-mRNA ceRNA network in letrozole-induced PCOS rat model and verified it by quantitative real-time polymerase chain reaction (qRT-PCR) experiment (10). Microarray analysis of tissues from women with and without PCOS allows the differentially expressed mRNA and non-coding RNA expression profiles to be determined.

Mural granulosa cells (MGCs), which surround follicles, provide nutrients and growth regulators to oocytes during their development (11). Besides, MGCs

participate in the arrest of oocytes in the meiotic phase through their secretion of oocyte maturation inhibitor (OMI) (12). Thus, dysfunction of MGCs may contribute to the aberrant folliculogenesis observed in PCOS. For the current research, the lncRNA, miRNA, and mRNA expression profiles of MGCs in women with and without PCOS were obtained. Subsequently, we established the lncRNA-miRNA-mRNA network in PCOS based on the ceRNA theory. We aimed to provide novel insights into the lncRNA-miRNA-mRNA interaction network and its related pathways in PCOS, and to provide theoretical perspectives to inform future research on PCOS occurrence and development.

We present the following article in accordance with the MDAR reporting checklist (available at <https://dx.doi.org/10.21037/atm-21-2696>).

Methods

Microarray data

The National Center for Biotechnology Information (NCBI)'s Gene Expression Omnibus (GEO) repository (<https://www.ncbi.nlm.nih.gov/geo/>) was searched for gene expression profile datasets of MGCs from women with PCOS and healthy women without PCOS. The GEO repository is a public database that stores chip, second-generation sequencing, and other high-throughput sequencing data. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The keywords for the search included “polycystic ovary syndrome”, “PCOS”, “granulosa cells”, and “homo sapiens”. GSE84376 and GSE106724 were selected for further analyses (Figure 1). The GSE84376 dataset (platform: GPL16384, Affymetrix Multispecies miRNA-3 Array) contains 13 PCOS samples and 15 non-PCOS samples. The GSE106724 dataset (platform: GPL21096, Affymetrix Human Genome U133 Plus 2.0 Array Affymetrix Human Clariom D Assay) consists of 8 PCOS samples and 4 non-PCOS samples.




Figure 1 Flowchart of data processing and analysis. lncRNA, long non-coding RNA; miRNA, microRNA; mRNA, messenger RNA; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

Identification of differentially expressed mRNAs and non-coding RNAs

We screened the differentially expressed mRNAs and non-coding RNAs between the PCOS and non-PCOS samples using GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r>). We defined RNAs with $|\log FC| > 1$ and $P < 0.05$ as being differentially expressed.

Prediction and construction of the miRNA-mRNA network

Target genes of differentially expressed miRNAs were predicted using the DIANA-microT-CDS algorithm (<http://www.microrna.gr/microT-CDS>) (13). Target genes and miRNAs show contrasting alteration patterns in their differential expression. Cytoscape (<http://www.cytoscape.org/>) was employed to visualize the miRNA-mRNA regulatory network.

Constructing the lncRNA-miRNA-mRNA ceRNA network

lncRNA-miRNA interactions were predicted using DIANA-LncBase v2 (14). The lncRNAs and the miRNAs are differentially expressed with opposite expression alteration patterns. Then, the co-expressed competing triplets were assembled to obtain differentially expressed

lncRNA-miRNA-mRNA networks. Cytoscape was used for network visualization.

Functional and pathway enrichment analysis

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation of the differentially expressed genes (DEGs) related to PCOS was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>) (15). GO analysis examines genes with respect to their molecular functions (MFs), biological processes (BPs), and cellular components (CCs). We defined $P < 0.05$ as indicating statistical significance for both GO terms and KEGG pathways.

Protein-protein interaction (PPI) network generation and module analysis

The PPI network of the DEGs was analyzed by STRING (<https://string-db.org/>). The cut-off standard was defined as > 0.4 . We visualized the PPI network using Cytoscape. Hub genes were ranked by Cytoscape cytoHubba (16). Cytoscape MCODE was applied to screen modules within the PPI network and identify the central genes among the

Table 1 Top five GO and KEGG enrichment of DEGs in GSE106724

Category	Term	Gene function/pathway	Count	P value
BP	GO:0007155	Cell adhesion	21	2.0E-3
	GO:0009611	Response to wounding	7	2.1E-3
	GO:0035910	Ascending aorta morphogenesis	3	2.6E-3
	GO:0001525	Angiogenesis	13	3.0E-3
	GO:0046627	Negative regulation of insulin receptor signaling pathway	5	3.1E-3
CC	GO:0016021	Integral component of membrane	139	1.6E-3
	GO:0017053	Transcriptional repressor complex	6	6.5E-3
	GO:0005886	Plasma membrane	110	8.7E-3
	GO:0005667	Transcription factor complex	11	9.1E-3
	GO:0005884	Actin filament	6	1.3E-2
MF	GO:0031727	CCR2 chemokine receptor binding	3	1.3E-3
	GO:0042803	Protein homodimerization activity	28	3.6E-3
	GO:0005089	Rho guanyl-nucleotide exchange factor activity	7	5.8E-3
	GO:0008373	Protein kinase A binding	4	7.1E-3
	GO:0051018	Sialyltransferase activity	4	7.1E-3
KEGG pathway	hsa00830	Retinol metabolism	5	3.7E-2
	hsa00260	Glycine, serine and threonine metabolism	4	4.1E-2
	hsa00982	Drug metabolism—cytochrome P450	5	4.5E-2
	hsa05144	Malaria	4	7.2E-2
	hsa04390	Hippo signaling pathway	7	7.8E-2

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; BP, biological process; CC, cellular component; MF, molecular function.

DEGs (degree cutoff =2, max. depth =100, k-core =2, and node score cutoff =0.2) (16). The MCODE application in Cytoscape was utilized to examine the modules of the PPI network and identify the central genes among the DEGs (standard: degree cutoff =2, max. depth =100, k-core =2, and node score cutoff =0.2). Modules with an MCODE score >3 and nodes >5 were selected.

Results

Differentially expressed lncRNAs, miRNAs, and mRNAs

A total of 462 mRNAs, 2,464 lncRNAs, and 55 miRNAs were differentially expressed between the MGCs of patients with PCOS and those of healthy controls. Of them, 213 mRNAs, 392 lncRNAs, and 52 miRNAs were

over-expressed, while 249 mRNAs, 2,072 lncRNAs, and 3 miRNAs were under-expressed.

Functional enrichment and KEGG pathway analysis of the DEGs

Table 1 lists the GO terms and KEGG pathways of DEGs in GSE106724. The most significantly enriched BPs were cell adhesion, response to wounding, ascending aorta morphogenesis, angiogenesis, and negative regulation of insulin receptor signaling pathway. The KEGG pathways showing the most significant enrichment were retinol metabolism, drug metabolism—cytochrome P450, malaria, the Hippo signaling pathway, and glycine, serine and threonine metabolism.




Figure 2 PPI analysis. (A) The PPI network of DEGs from the GSE106724 dataset. Disconnected nodes in the network are hidden; (B) module 1 (score: 5); (C) module 2 (score: 4.8); (D) module 3 (score: 3.333); and (E) module 4 (score: 3.143). PPI, protein-protein interaction; DEGs, differentially expressed genes.

PPI network of the DEGs and module analysis

The PPI network of the 462 DEGs obtained from the GSE106724 dataset was established using STRING. It was composed of 420 nodes and 556 edges (Figure 2A). By overlapping the top 20 genes according to the degree and maximal clique centrality (MCC) methods in cytoHubba, we identified *CD163*, *MRC1*, *VSIG4*, *MSR1*, *UBR4*, *CCL2*, *CYBB*, *CCR2*, *SPP1*, *ESR1*, *LPL*, and *MGAM* as hub genes.

Four clusters from the PPI network were identified (Figure 2B,C,D,E). Module 1 comprised 23 nodes and 55 edges; module 2 comprised 6 nodes and 12 edges; module 3 consisted of 4 nodes and 5 edges; and module 4

contained 8 nodes and 11 edges. Enrichment analyses of module 1 demonstrated that the most significantly enriched BPs were protein ubiquitination involved in ubiquitin-dependent protein catabolic process, inflammatory response, and positive regulation of monocyte chemotaxis. For module 1, no KEGG pathway met the criterion for statistically significant enrichment ($P < 0.05$). The most significantly enriched BPs in module 2 included oxygen transport, bicarbonate transport, blood coagulation, hydrogen peroxide catabolic process, and positive regulation of cell death. The KEGG pathways in module 2 were mainly enriched in African trypanosomiasis and malaria.




Figure 4 The lncRNA-miRNA-mRNA ceRNA network. Diamond-shaped nodes represent lncRNAs; rectangular nodes represent miRNAs; and oval-shaped nodes represent mRNAs. Green represents downregulation and red shows co-upregulation. (A) The whole lncRNA-miRNA-mRNA ceRNA network; (B) the subnetworks of five hub miRNAs with their first neighbors. lncRNA, long non-coding RNA; miRNA, microRNA; mRNA, messenger RNA.

be *hsa-miR-3135b*, *hsa-miR-4649-3p*, *hsa-miR-1231*, *hsa-miR-3609*, and *hsa-miR-4433b-3p*. The subnetworks of these five hub miRNAs and their first neighbors are presented in Figure 4B. We picked the subnetworks of four hub miRNAs (*hsa-miR-3135b*, *hsa-miR-4649-3p*, *hsa-miR-3609*, and *hsa-miR-4433b-3p*) for further analysis. These four miRNAs interacted with 34 lncRNAs and 42 mRNAs. The most enriched BPs included negative regulation of apoptotic process, osteoblast development, protein ubiquitination involved in ubiquitin-dependent protein catabolic process, pituitary gland development, and chondrocyte differentiation. The most enriched CCs included cytosol and extracellular vesicles. The most enriched MFs were sodium channel regulator activity and protein binding. No KEGG pathway met the criterion for statistically significant enrichment ($P < 0.05$).

Discussion

PCOS constitutes one of the most prevalent endocrine disorders affecting women of childbearing age. Although

PCOS is etiologically multifactorial, genetic abnormality is thought to be a key cause. Recent microarray studies have identified some differentially expressed lncRNAs, miRNAs, and mRNAs as being involved in PCOS. Based on the ceRNA hypothesis, lncRNAs are referred to as miRNA sponges, owing to their ability to bind and sequester miRNAs in order to exert a regulatory effect (17,18). Thus, in-depth insight into lncRNA-miRNA-mRNA interactions will improve the understanding of the occurrence and development of PCOS.

In this study, we identified a total of 462 mRNAs, 2,464 lncRNAs, and 55 miRNAs as being differentially expressed between the MGCs of women with PCOS and those of healthy women. Among the DEGs, *CD163*, *MRC1*, *VSIG4*, *MSR1*, *UBR4*, *CCL2*, *CYBB*, *CCR2*, *SPP1*, *ESR1*, *LPL*, and *MGAM* were identified as hub genes. *CD163* is an endocytic scavenger receptor that serves as a marker of macrophage activation in adipose tissue. Circulating soluble *CD163* is frequently associated with obesity and metabolic disorders (19). Møller *et al.* found an elevated serum level of soluble *CD163* to be a predictive factor for type 2 diabetes mellitus

Table 2 Top five GO enrichment of DEGs in lncRNA-miRNA-mRNA ceRNA network

Category	Term	Gene function/pathway	Count	P value
BP	GO:0043066	Negative regulation of apoptotic process	7	4.0E-3
	GO:0042787	Protein ubiquitination involved in ubiquitin-dependent protein catabolic process	4	1.4E-2
	GO:0006281	DNA repair	4	4.4E-2
	GO:0002076	Osteoblast development	2	5.5E-2
	GO:0006883	Cellular sodium ion homeostasis	2	6.2E-2
CC	GO:1903561	Extracellular vesicle	3	1.2E-2
	GO:0016324	Apical plasma membrane	5	1.6E-2
	GO:0005829	Cytosol	19	2.1E-2
	GO:0015629	Actin cytoskeleton	4	3.7E-2
	GO:0016020	Membrane	13	5.9E-2
MF	GO:0017080	Sodium channel regulator activity	3	5.9E-3
	GO:0005546	Phosphatidylinositol-4,5-bisphosphate binding	3	1.9E-2
	GO:0010314	Phosphatidylinositol-5-phosphate binding	2	4.3E-2
	GO:0070300	Phosphatidic acid binding	2	5.6E-2
	GO:0005545	1-phosphatidylinositol binding	2	7.0E-2

GO, Gene Ontology; DEGs, differentially expressed genes; lncRNA, long non-coding RNA; miRNA, microRNA; mRNA, messenger RNA; BP, biological process; CC, cellular component; MF, molecular function.

in an age- and body mass index-independent manner (20). *MRC1* is a conserved replication fork factor that stabilizes stalled forks and plays an essential role in checkpoint signal transmission (21). When the S-phase checkpoint becomes activated following DNA damage, *MRC1* is critical for cell-cycle reentry (22). *VSIG4* is a complement receptor belong to the immunoglobulin superfamily and is only expressed by a subset of macrophages which reside in tissues. A protective effect of the *VSIG4*-Fc fusion protein has been reported in experiments on the development of autoimmune arthritis, uveoretinitis, and hepatitis (23). *MSR1* is a macrophage scavenger receptor that has been reported to participate in the maintenance of immunological tolerance (24). *UBR4* belongs to the mammalian N-recogin family. Tasaki *et al.* found that mice with *UBR4* deficiency died during embryogenesis and exhibited pleiotropic abnormalities, such as vascular development impairment in the yolk sac (25). *CCL2* is a chemokine which promotes cell migration by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma (26), and its receptor is *CCR2* (27). *SPP1* is a secreted non-collagenous protein that acts as a cytokine. It is likely important to cell-matrix interaction, and can regulate several cell behaviors and modulate leukocyte

migration (28). *ESR1* gene polymorphisms have been found to be involved in the phenotype of complications of PCOS (29). *LPL* is a key lipolysis-associated factor which is associated with obesity. Finally, *MGAM* appears to have great diagnostic value for type 2 diabetes mellitus (30).

Our lncRNA-miRNA-mRNA ceRNA network comprises 71 under-expressed lncRNA nodes, 14 over-expressed miRNA nodes, and 69 under-expressed mRNA nodes. The top five hub miRNAs included *hsa-miR-3135b*, *hsa-miR-4649-3p*, *hsa-miR-1231*, *hsa-miR-3609*, and *hsa-miR-4433b-3p*. Wang *et al.* found that *hsa-miR-3135b* in granulosa cells was significantly negatively correlated with follicle-stimulating hormone. Receiver operating characteristic (ROC) curve analysis revealed that the accuracy of *hsa-miR-3135b* in diagnosing PCOS was 0.760, with a sensitivity of 62.5% and a specificity of 85.7% (31). Zhang *et al.* found that *miR-1231* was expressed at reduced levels in human glioma tissues and had a negative correlation epidermal growth factor receptor (*EGFR*) expression. Further, luciferase assay verified that *miR-1231* directly targets *EGFR*, and when overexpressed, *EGFR* inhibited the suppression of the PI3K/AKT pathway and G1 arrest induced by *miR-1231* (32). At present, little research has been done on *hsa-miR-4649-*

3p, *hsa-miR-3609*, and *hsa-miR-4433b-3p*. This study also identified several 41 differentially expressed lncRNAs which interact with hub miRNAs in the ceRNA network, including NONHSAT018285.2, NONHSAT142592.2, NONHSAT112972.2, and NONHSAT012542.2; however, little research has been done on these lncRNAs.

Although our study provides important information for elucidating the development of PCOS and provides a theoretical basis for future research, these mechanisms have not been experimentally confirmed; further *in vivo* and *in vitro* experiments are needed to validate our findings.

Conclusions

This study identified a novel lncRNA-miRNA-mRNA network based on the ceRNA mechanism in PCOS. Some novel genes and non-coding RNAs that may be involved in the occurrence and development of PCOS were excavated, including *CD163*, *MRC1*, *VSIG4*, *CCL2*, *CCR2*, *SPP1*, *hsa-miR-3135b*, *hsa-miR-4649-3p*, *hsa-miR-1231*, *hsa-miR-3609*, and *hsa-miR-4433b-3p*. We have unearthed important information to elucidate the development of PCOS, which may provide a theoretical basis for future studies. However, *in vivo* and *in vitro* experiments are needed to validate our findings.

Acknowledgments

Funding: This work was supported by grants from Key Research and Development Programs of Science and Technology Bureau of Sichuan Province (grant No. 2019YFS0421).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://dx.doi.org/10.21037/atm-21-2696>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/atm-21-2696>). Dr. HC reports that this work was supported by grants from Key Research and Development Programs of Science and Technology Bureau of Sichuan Province (grant No. 2019YFS0421). The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related

to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This research did not involve human subject trial. Instead, the data came exclusively from the Gene Expression Omnibus. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 2004;81:19-25.
2. Aydos A, Gurel A, Oztumur Islakoglu Y, et al. Identification of polycystic ovary syndrome (PCOS) specific genes in cumulus and mural granulosa cells. *PLoS One* 2016;11:e0168875.
3. Shi X, Sun M, Liu H, et al. Long non-coding RNAs: a new frontier in the study of human diseases. *Cancer Lett* 2013;339:159-66.
4. Ning M, Qin S, Tian J, et al. LncRNA AFAP-AS1 promotes anaplastic thyroid cancer progression by sponging miR-155-5p through ETS1/ERK pathway. *Bioengineered* 2021;12:1543-54.
5. Luo X, Shi Q, Gu Y, et al. LncRNA pathway involved in premature preterm rupture of membrane (PPROM): an epigenomic approach to study the pathogenesis of reproductive disorders. *PLoS One* 2013;8:e79897.
6. Ergun S, Oztuzcu S. Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways. *Tumour Biol* 2015;36:3129-36.
7. Piao Z, Zou R, Lin Y, et al. Overexpression of lncRNA H19 leads to reduced proliferation in TSCC cells through miR-675-5p/GPR55. *Transl Cancer Res* 2020;9:891-900.
8. Jiang B, Xue M, Xu D, et al. Down-regulated lncRNA HOTAIR alleviates polycystic ovaries syndrome in rats by reducing expression of insulin-like growth factor 1 via microRNA-130a. *J Cell Mol Med* 2020;24:451-64.

9. Xiong W, Lin Y, Xu L, et al. Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population. *J Ovarian Res* 2017;10:10.
10. Fu LL, Xu Y, Li DD, et al. Expression profiles of mRNA and long noncoding RNA in the ovaries of letrozole-induced polycystic ovary syndrome rat model through deep sequencing. *Gene* 2018;657:19-29.
11. Munakata Y, Kawahara-Miki R, Shiratsuki S, et al. Gene expression patterns in granulosa cells and oocytes at various stages of follicle development as well as in in vitro grown oocyte-and-granulosa cell complexes. *J Reprod Dev* 2016;62:359-66.
12. Kawamura K, Cheng Y, Kawamura N, et al. Pre-ovulatory LH/hCG surge decreases C-type natriuretic peptide secretion by ovarian granulosa cells to promote meiotic resumption of pre-ovulatory oocytes. *Hum Reprod* 2011;26:3094-101.
13. Liu X, Chen J, Guan T, et al. miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson's disease. *BMC Syst Biol* 2019;13:10.
14. Paraskevopoulou MD, Vlachos IS, Karagkouni D, et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. *Nucleic Acids Res* 2016;44:D231-8.
15. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44-57.
16. Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 2014;8 Suppl 4:S11.
17. Tan JY, Sirey T, Honti F, et al. Extensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse embryonic stem cells. *Genome Res* 2015;25:655-66.
18. Duan X, Wu Y, Zhang Z, et al. Identification and analysis of dysregulated lncRNA and associated ceRNA in the pathogenesis of keloid. *Ann Transl Med* 2020;8:222.
19. Parkner T, Sørensen LP, Nielsen AR, et al. Soluble CD163: a biomarker linking macrophages and insulin resistance. *Diabetologia* 2012;55:1856-62.
20. Møller HJ, Frikke-Schmidt R, Moestrup SK, et al. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. *Clin Chem* 2011;57:291-7.
21. Katou Y, Kanoh Y, Bando M, et al. S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex. *Nature* 2003;424:1078-83.
22. Chaudhury I, Koepp DM. Degradation of Mrc1 promotes recombination-mediated restart of stalled replication forks. *Nucleic Acids Res* 2017;45:2558-70.
23. He JQ, Wiesmann C, van Lookeren Campagne M. A role of macrophage complement receptor CR1g in immune clearance and inflammation. *Mol Immunol* 2008;45:4041-7.
24. Haasken S, Auger JL, Taylor JJ, et al. Macrophage scavenger receptor 1 (Msr1, SR-A) influences B cell autoimmunity by regulating soluble autoantigen concentration. *J Immunol* 2013;191:1055-62.
25. Tasaki T, Kim ST, Zakrzewska A, et al. UBR box N-recogin-4 (UBR4), an N-recogin of the N-end rule pathway, and its role in yolk sac vascular development and autophagy. *Proc Natl Acad Sci U S A* 2013;110:3800-5.
26. Ling Z, Yang X, Chen X, et al. CCL2 promotes cell migration by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. *J Oral Pathol Med* 2019;48:477-82.
27. Peña CG, Nakada Y, Saatcioglu HD, et al. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. *J Clin Invest* 2015;125:4063-76.
28. Song SZ, Lin S, Liu JN, et al. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway. *J Cell Physiol* 2019;234:18587-601.
29. Silva FS, Sóter MO, Sales MF, et al. Estrogen receptor alpha gene (ESR1) PvuII and XbaI polymorphisms are associated to metabolic and proinflammatory factors in polycystic ovary syndrome. *Gene* 2015;560:44-9.
30. Laoud A, Ferkous F, Maccari L, et al. Identification of novel nt-MGAM inhibitors for potential treatment of type 2 diabetes: Virtual screening, atom based 3D-QSAR model, docking analysis and ADME study. *Comput Biol Chem* 2018;72:122-35.
31. Wang Y, Xu S, Wang Y, et al. Identification and potential value of candidate microRNAs in granulosa cells of polycystic ovary syndrome. *Technol Health Care* 2019;27:579-87.
32. Zhang J, Zhang J, Qiu W, et al. MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma. *J Neurooncol* 2018;139:547-62.

(English Language Editor: J. Reynolds)

Cite this article as: Chen H, Cheng S, Xiong W, Tan X. The lncRNA-miRNA-mRNA ceRNA network in mural granulosa cells of patients with polycystic ovary syndrome: an analysis of Gene Expression Omnibus data. *Ann Transl Med* 2021;9(14):1156. doi: 10.21037/atm-21-2696